Results 131 to 140 of about 9,613 (181)

Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies. [PDF]

J Clin Med
Nastase AG, Vasilescu AM, Trofin AM, Iftimie NF, Segura-Sampedro JJ, Cadar R, Buzincu I, Davidescu A, Nastase AL, Briceanu OG, Lupascu-Ursulescu C, Lupascu CD.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alternative roles for CD59

Molecular Immunology, 2007
CD59 was first identified as a regulator of the terminal pathway of complement, which acts by binding to the C8/C9 components of the assembling membrane attack complex (MAC), to inhibit formation of the lytic pore. Structurally, CD59 is a small, highly glycosylated, GPI-linked protein, with a wide expression profile.
Paul Morgan, Baalasubramanian Sivasankar   +1 more
exaly   +3 more sources

CD59: A Promising Target for Tumor Immunotherapy

Future Oncology, 2018
CD59 has been identified as a glycosylphosphatidylinositol-anchored membrane protein that acts as an inhibitor of the formation of the membrane attack complex to regulate complement activation. Recent studies have shown that CD59 is highly expressed in several cancer cell lines and tumor tissues.
Yupei Zhao, Qiaofei Liu, Ronghua Zhang   +2 more
exaly   +3 more sources

Congenital CD59 Deficiency

Hematology/Oncology Clinics of North America, 2015
The severe clinical symptoms of inherited CD59 deficiency confirm the importance of CD59 as essential complement regulatory protein for protection of cells against complement attack, in particular protection of hematopoietic cells and human neuronal tissue.
Britta, Höchsmann, Hubert, Schrezenmeier   +1 more
openaire   +2 more sources

Evolution of cd59 gene in mammals

Science in China Series C: Life Sciences, 2007
The CD59-coding sequences were obtained from 5 mammals by PCR and BLAST, and combined with the available sequences in GenBank, the nucleotide substitution rates of mammalian cd59 were calculated. Results of synonymous and nonsynonymous substitution rates revealed that cd59 experienced negative selection in mammals overall.
YuanYing, Gong, MinSheng, Peng, WeiPing, Zhou, YaPing, Zhang   +3 more
openaire   +2 more sources

The expression of CD59 in experimental allergic neuritis

Journal of the Neurological Sciences, 1999
Complement is implicated as an effector in inflammatory demyelination occurring in Guillain-Barré syndrome (GBS) and in experimental allergic neuritis (EAN). CD59, a potent complement regulatory protein that inhibits the formation of the terminal cytolytic membrane attack complex (MAC), is expressed on human and rat Schwann cells. In EAN the expression
C. A. Vedeler, G. Conti, T. Fujioka, E. Scarpini, A. Rostami   +4 more
openaire   +2 more sources

A rapid method for the isolation of analogues of human CD59 by preparative SDS-PAGE: application to pig CD59

Journal of Immunological Methods, 1995
A method for the rapid isolation of functionally active analogues of human CD59 from erythrocytes (E) is described. The method, here applied to pig E, is based on the fractionation of a butanol extract of E ghosts by preparative SDS-PAGE followed by gel filtration on Superose 12. Purification was monitored using a functional complement inhibition assay.
C W, van den Berg, R A, Harrison, B P, Morgan   +2 more
openaire   +2 more sources

Acute promyelocytic leukemia with CD59 deficiency

Leukemia Research, 1993
CD59 is a phosphatidyl inositol-anchored protein (which is lost in paroxysmal nocturnal hemoglobinuria (PNH) cells) with the capacity to block the formation of membrane attack complex, and protects host cells from autologous complement-mediated cytolysis.
T, Seya, H, Tejima, H, Fukuda, T, Hara, M, Matsumoto, M, Hatanaka, Y, Sugita, T, Masaoka   +7 more
openaire   +2 more sources

Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line.

Immunology, 1994
U937 cells are known to be relatively sensitive to C-mediated killing and have been reported to show variable expression of CD59. We have obtained stable CD59+ and CD59- sublines of the U937 cell line. Expression of other C-regulatory proteins, decay-accelerating factor (DAF), MCP and CR1, was similar on both cell lines.
C W, van den Berg, O M, Williams, B P, Morgan   +2 more
openaire   +1 more source

Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation

Annals of Neurology, 2016
Objective The objective of this work was to report on the outcome of eculizumab treatment in pediatric patients with recurrent acute predominantly motor, demyelinating neuropathy with conduction block, and chronic hemolysis attributed to p.Cys89Tyr mutation in the ...
Dror, Mevorach, Inna, Reiner, Amir, Grau, Uri, Ilan, Yackov, Berkun, Asaf, Ta-Shma, Orly, Elpeleg, Zamir, Shorer, Simon, Edvardson, Adi, Tabib   +9 more
openaire   +2 more sources